Medical and regulatory affairs teams at sponsors use this agent when designing individual patient or intermediate-size expanded access programmes under FDA 21 CFR 312 Subpart I or EMA compassionate use frameworks, particularly for oncology or rare disease candidates where patients face serious or immediately life-threatening conditions with no alternatives. The tension between access speed and regulatory compliance creates high-stakes decisions.